Search

Edwards Lifesciences Corp

Închisă

SectorSănătate

92.26 1.42

Rezumat

Modificarea prețului

24h

Curent

Minim

90.19

Maxim

91.64

Indicatori cheie

By Trading Economics

Venit

-139M

241M

Vânzări

92M

1.7B

P/E

Medie Sector

54.054

57.371

EPS

0.78

Marjă de profit

13.866

Angajați

16,000

EBITDA

20M

520M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+13.29% upside

Dividende

By Acuity

Următoarele câștiguri

29 oct. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3B

52B

Deschiderea anterioară

90.84

Închiderea anterioară

92.26

Sentimentul știrilor

By Acuity

33%

67%

112 / 340 Clasament în Healthcare

Edwards Lifesciences Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 aug. 2026, 23:06 UTC

Edwards Lifesciences shares are lower in after-market hours amid rising U.S. bond yields, contributing to market concerns despite recent softer economic data.

13 aug. 2026, 20:06 UTC

Edwards Lifesciences shares are lower today, tracking a broader market decline. The stock remains above its 20-day moving average and near its one-month range.

12 aug. 2026, 22:16 UTC

Edwards Lifesciences shares declined in after-market trading, despite earlier fluctuations. The stock remains above its 20-day moving average and near its one-month range.

11 aug. 2026, 19:21 UTC

Edwards Lifesciences Corp is trading higher, maintaining upward momentum after four consecutive daily gains and peaking in the late morning session.

10 aug. 2026, 19:51 UTC

Edwards Lifesciences shares are higher today, reflecting unusual strength above the 20-day moving average amid uncertainty over the Federal Reserve's interest rate policy.

7 aug. 2026, 19:16 UTC

Edwards Lifesciences Corp. shares are higher today, fluctuating within a routine range since Thursday's close, currently trading above its 20-day moving average.

5 aug. 2026, 19:56 UTC

Edwards Lifesciences shares are lower today, continuing a decline since Tuesday. The stock remains above its 20-day moving average.

4 aug. 2026, 19:36 UTC

Edwards Lifesciences shares are higher amid positive market momentum, despite a notable decline in U.S. core factory orders reflecting weakening demand across sectors.

3 aug. 2026, 22:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, following a notable decline that reached a session low shortly after the market opened.

31 iul. 2026, 19:46 UTC

Edwards Lifesciences shares are lower, reflecting broader market trends amid inflation and interest rate concerns. The stock is trading below its 20-day moving average.

30 iul. 2026, 22:06 UTC

Edwards Lifesciences shares are trading lower in after-market hours, reflecting ongoing weakness and uncertainty following the Federal Reserve's interest rate decision.

29 iul. 2026, 23:46 UTC

Edwards Lifesciences Corp shares are higher in after-market trading, following four consecutive sessions of gains. No specific news was identified to explain the movement.

28 iul. 2026, 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 iul. 2026, 19:41 UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 iul. 2026, 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 iul. 2026, 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 iul. 2026, 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 iul. 2026, 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 iul. 2026, 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Comparație

Modificare preț

Edwards Lifesciences Corp Așteptări

Obiectiv de preț

By TipRanks

13.29% sus

Prognoză pe 12 luni

Medie 102.88 USD  13.29%

Maxim 110 USD

Minim 85 USD

În baza a 19 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEdwards Lifesciences Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

19 ratings

16

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

112 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat